Qihan Biotech Appoints Yingyong Xu as its Chief Medical Officer
Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today the appointment of Mr. Yingyong Xu as the Chief Medical Officer.
- Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today the appointment of Mr. Yingyong Xu as the Chief Medical Officer.
- Mr. Yingyong Xu brings over two decades of specialized expertise in clinical treatment and innovative drug development in hematology and oncology.
- Dr. Luhan Yang, Founder and CEO of Qihan Biotech, stated, "We are delighted to welcome Mr. Yingyong Xu to Qihan.
- Under the leadership of Dr. Luhan Yang, the Qihan team will bring revolutionary treatment modalities to patients", Mr. Xu said.